|
|
|
| Webinar: When Biologics Supply Can’t Fail: How Sponsors Should Evaluate Manufacturing Resilience | Biologics supply resilience is now a critical factor in successful outsourcing decisions. Join this Boehringer Ingelheim webinar to learn how to evaluate CDMO partners beyond capacity, assessing manufacturing readiness, quality systems, technical expertise and business continuity strategies. Gain practical guidance to reduce supply risk, strengthen long-term program success and confidently select partners that support reliable biologics manufacturing. Click here to learn more. |
|
|
|
|
|
| Becoming A Cornerstone Of A CDMO Strategy In Denmark | Article | By Christian Houborg, FUJIFILM Biotechnologies | Take a look at how modular design, digitalized quality systems, and sustainability-focused infrastructure are reshaping manufacturing, enabling faster paths from development to commercial supply. |
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | AI may help run and optimize bioreactors at your CDMO. There is pervasive pressure to move manual (and reactive) control to AI-autonomous (predictive systems). You may already select your CDMO partially based on its systematic utilization of AI in its facilities. But at this moment of transition, while the odds are high AI may not fully reside in the manufacturing plant today, it increasingly shapes the decisions determining what and how programs get to that plant. | |
|
|
Strategic CDMO Partnerships: From Vendor To Collaborative Partner | By The Outsourcing Advisor podcast | Many pharma companies are shifting from one-off, fee-for-service deals to deeper long-term partnerships with their CDMOs, emphasizing shared goals and transparency. In this episode, editorial board members Doug Bakan and Kim Burson discuss how to transform the sponsor-CDMO dynamic. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
| Step Into The Future Of Chromatography Automation | Article | Cytiva | As downstream processing grows more connected and complex, chromatography remains a key automation challenge. See how flexibility and stronger control are shaping more practical workflows. |
|
|
|
| Streamlining Process Characterization Toward Validation Campaigns | Article | By Claudia Berdugo-Davis, Ph.D., and Danielle Wittenwyler, Ph.D., Catalent | Compress your biologics process characterization timeline without sacrificing quality. Assimilate how FMEA, DoE, and platform approaches help you hit PPQ readiness faster while managing regulatory risk. |
|
|
|
|
|
|
| Outsourced Pharma Capabilities Update - ADCs | This digital event focuses on antibody-drug conjugates (ADCs) and how CDMOs support their development from early stages through clinical and commercial manufacturing. It highlights the importance of selecting the right partner for these complex therapies, including expertise in conjugation processes, scalability, regulatory needs, and integrated development services. Attendees will learn key criteria for evaluating CDMOs and how to align partnerships to accelerate ADC program success. Click here to learn more. |
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
